Immatics N.V. (IMTX) stock
IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.39−0.13 (-1.99%)
Close on Nov 13, 2026Market cap $856.72MP/E –Yield –
Immatics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -€169.62M. The highest annual figure on record is €36.92M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€169.62M | – |
| FY2024 | Dec 31, 2024 | -€26.39M | – |
| FY2023 | Dec 31, 2023 | -€94.49M | -355.9% |
| FY2022 | Dec 31, 2022 | €36.92M | – |
| FY2021 | Dec 31, 2021 | -€81.03M | – |
| FY2020 | Dec 31, 2020 | -€65.29M | – |
| FY2019 | Dec 31, 2019 | -€29.16M | – |
| FY2018 | Dec 31, 2018 | -€32.23M | – |
See a number that looks wrong?